Histogenics Corp. plans to offer its common shares and accompanying warrants to buy common shares in an underwritten public offering.
All of the securities being issued in the offering will be sold by the clinical-stage company.
The Waltham, Mass.-based company plans to use the net proceeds from the offering to submit the biologics license application and prepare for marketing of NeoCart, a tissue implant, following approval by the U.S. Food and Drug Administration.
NeoCart is a tissue implant in a phase 3 study to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
In addition, the net proceeds will be used for general corporate purposes.
Canaccord Genuity LLC and BTIG LLC are acting as the joint book-running managers for the offering.